Analyst Lili (Aurélie) Nsongo from Leerink Partners reiterated a Buy rating on Arcturus Therapeutics (ARCT – Research Report) and keeping the price target at $63.00.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Lili (Aurélie) Nsongo’s rating is based on several promising developments within Arcturus Therapeutics. The company is making significant progress in its internal rare disease pipeline, with ongoing enrollment in the Phase 2 study of ARCT-032 for cystic fibrosis and expected interim data by mid-2025. Additionally, Arcturus is advancing its ARCT-810 program for OTC deficiency, with interim data anticipated in the second quarter of 2025, which will provide critical biomarker and functional data.
Moreover, the company is strategically managing its financial resources, extending its cash runway into 2028 through cost-saving measures such as facilities consolidation and the elimination of early-stage R&D programs. This financial prudence, combined with the expected regulatory filings for its partnered COVID vaccine, Kostaive, in the UK and US, positions Arcturus for potential commercial success. These factors contribute to the positive outlook and the Buy rating for Arcturus Therapeutics.
According to TipRanks, (Aurélie) Nsongo is ranked #9300 out of 9511 analysts.
In another report released yesterday, Canaccord Genuity also maintained a Buy rating on the stock with a $66.00 price target.